| Brian D Weber, MD | |
|
705 Dixie Street, Carrollton, GA 30117 | |
| (770) 834-0751 | |
| (770) 834-0753 |
| Full Name | Brian D Weber |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 16 Years |
| Location | 705 Dixie Street, Carrollton, Georgia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356502538 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 072844 (Georgia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hillcrest Hospital | Mayfield heights, OH | Hospital |
| Mercy Medical Center | Canton, OH | Hospital |
| Akron General Medical Center | Akron, OH | Hospital |
| Cleveland Clinic | Cleveland, OH | Hospital |
| Fairview Hospital | Cleveland, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Clinic Medical Services Company | 5698674653 | 274 |
News Archive
iPierian, Inc., the leading biopharmaceutical company using patient-derived induced pluripotent stem cells (iPSCs) for drug discovery, today announced the closing of a $22 million Series B equity financing. The financing round was led by new investor Google Ventures, and was joined by Mitsubishi UFJ Capital and ATEL Ventures. All current investors also participated, including: Kleiner Perkins Caufield & Byers, Highland Capital Partners, MPM Capital and FinTech Global Capital.
Baxter International Inc. today announced initiation of a Phase III clinical trial to evaluate the safety and effectiveness of BAX 111, Baxter's investigational recombinant von Willebrand factor (rVWF), for the treatment and prevention of bleeding episodes in patients with von Willebrand disease.
The appearance of a deadly new strain of tuberculosis (TB) has so concerned the World Health Organisation (WHO) that an emergency meeting of health experts has been convened in Johannesburg to discuss the issue.
Super-agers, or individuals whose cognitive skills are above the norm even at an advanced age, have been found to have increased resistance to tau and amyloid proteins, according to research presented at the Society of Nuclear Medicine and Molecular Imaging 2020 Annual Meeting.
› Verified 9 days ago
| Entity Name | Clinic Medical Services Company |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528013984 PECOS PAC ID: 5698674653 Enrollment ID: O20070709000113 |
News Archive
iPierian, Inc., the leading biopharmaceutical company using patient-derived induced pluripotent stem cells (iPSCs) for drug discovery, today announced the closing of a $22 million Series B equity financing. The financing round was led by new investor Google Ventures, and was joined by Mitsubishi UFJ Capital and ATEL Ventures. All current investors also participated, including: Kleiner Perkins Caufield & Byers, Highland Capital Partners, MPM Capital and FinTech Global Capital.
Baxter International Inc. today announced initiation of a Phase III clinical trial to evaluate the safety and effectiveness of BAX 111, Baxter's investigational recombinant von Willebrand factor (rVWF), for the treatment and prevention of bleeding episodes in patients with von Willebrand disease.
The appearance of a deadly new strain of tuberculosis (TB) has so concerned the World Health Organisation (WHO) that an emergency meeting of health experts has been convened in Johannesburg to discuss the issue.
Super-agers, or individuals whose cognitive skills are above the norm even at an advanced age, have been found to have increased resistance to tau and amyloid proteins, according to research presented at the Society of Nuclear Medicine and Molecular Imaging 2020 Annual Meeting.
› Verified 9 days ago
| Entity Name | Cleveland Clinic Health Services Professional Association Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770082471 PECOS PAC ID: 3577813005 Enrollment ID: O20220906001362 |
News Archive
iPierian, Inc., the leading biopharmaceutical company using patient-derived induced pluripotent stem cells (iPSCs) for drug discovery, today announced the closing of a $22 million Series B equity financing. The financing round was led by new investor Google Ventures, and was joined by Mitsubishi UFJ Capital and ATEL Ventures. All current investors also participated, including: Kleiner Perkins Caufield & Byers, Highland Capital Partners, MPM Capital and FinTech Global Capital.
Baxter International Inc. today announced initiation of a Phase III clinical trial to evaluate the safety and effectiveness of BAX 111, Baxter's investigational recombinant von Willebrand factor (rVWF), for the treatment and prevention of bleeding episodes in patients with von Willebrand disease.
The appearance of a deadly new strain of tuberculosis (TB) has so concerned the World Health Organisation (WHO) that an emergency meeting of health experts has been convened in Johannesburg to discuss the issue.
Super-agers, or individuals whose cognitive skills are above the norm even at an advanced age, have been found to have increased resistance to tau and amyloid proteins, according to research presented at the Society of Nuclear Medicine and Molecular Imaging 2020 Annual Meeting.
› Verified 9 days ago
| Entity Name | The Cleveland Clinic Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679525919 PECOS PAC ID: 1850203555 Enrollment ID: O20240110000303 |
News Archive
iPierian, Inc., the leading biopharmaceutical company using patient-derived induced pluripotent stem cells (iPSCs) for drug discovery, today announced the closing of a $22 million Series B equity financing. The financing round was led by new investor Google Ventures, and was joined by Mitsubishi UFJ Capital and ATEL Ventures. All current investors also participated, including: Kleiner Perkins Caufield & Byers, Highland Capital Partners, MPM Capital and FinTech Global Capital.
Baxter International Inc. today announced initiation of a Phase III clinical trial to evaluate the safety and effectiveness of BAX 111, Baxter's investigational recombinant von Willebrand factor (rVWF), for the treatment and prevention of bleeding episodes in patients with von Willebrand disease.
The appearance of a deadly new strain of tuberculosis (TB) has so concerned the World Health Organisation (WHO) that an emergency meeting of health experts has been convened in Johannesburg to discuss the issue.
Super-agers, or individuals whose cognitive skills are above the norm even at an advanced age, have been found to have increased resistance to tau and amyloid proteins, according to research presented at the Society of Nuclear Medicine and Molecular Imaging 2020 Annual Meeting.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Brian D Weber, MD Po Box 116186, Atlanta, GA 30368-6186 Ph: (770) 834-0751 | Brian D Weber, MD 705 Dixie Street, Carrollton, GA 30117 Ph: (770) 834-0751 |
News Archive
iPierian, Inc., the leading biopharmaceutical company using patient-derived induced pluripotent stem cells (iPSCs) for drug discovery, today announced the closing of a $22 million Series B equity financing. The financing round was led by new investor Google Ventures, and was joined by Mitsubishi UFJ Capital and ATEL Ventures. All current investors also participated, including: Kleiner Perkins Caufield & Byers, Highland Capital Partners, MPM Capital and FinTech Global Capital.
Baxter International Inc. today announced initiation of a Phase III clinical trial to evaluate the safety and effectiveness of BAX 111, Baxter's investigational recombinant von Willebrand factor (rVWF), for the treatment and prevention of bleeding episodes in patients with von Willebrand disease.
The appearance of a deadly new strain of tuberculosis (TB) has so concerned the World Health Organisation (WHO) that an emergency meeting of health experts has been convened in Johannesburg to discuss the issue.
Super-agers, or individuals whose cognitive skills are above the norm even at an advanced age, have been found to have increased resistance to tau and amyloid proteins, according to research presented at the Society of Nuclear Medicine and Molecular Imaging 2020 Annual Meeting.
› Verified 9 days ago
Jason Chase Sanders Ii, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 165 Clinic Ave, Carrollton, GA 30117 Phone: 770-836-9824 Fax: 770-836-9850 | |
Dr. Thomas Lewis Sistrunk, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 705 Dixie St, Carrollton, GA 30117 Phone: 770-836-9660 Fax: 770-812-5028 | |
Alexandre Morin, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 119 Maple St, Suite 205, Carrollton, GA 30117 Phone: 770-834-0751 Fax: 770-834-0753 | |
Dr. Robert S Hyslop, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 705 Dixie Street, Carrollton, GA 30117 Phone: 770-834-0751 Fax: 770-834-0753 | |
Michael S Pont, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 705 Dixie Street, Carrollton, GA 30117 Phone: 770-834-0751 Fax: 770-834-0753 | |
Dr. Anil A Dhople, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 165 Clinic Ave, Carrollton, GA 30117 Phone: 770-836-9824 Fax: 770-836-9850 |